NCT05712889
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05712889
Title Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Vincerx Pharma, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Honor Health Scottsdale Arizona 85258 United States Details
NEXT Austin Austin Texas 78758 United States Details
NEXT Oncology San Antonio San Antonio Texas 78229 United States Details
Macquarie University Macquarie Park New South Wales 2109 Australia Details
ICON Brisbane Brisbane Queensland 4101 Australia Details
ICON Adelaide Adelaide Southern Australia 5037 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field